SPHRY (SPHRY) Stock Price & Analysis
SPHRY (SPHRY) fell 7.76% to USD 5.35 as of September 9, 2026 at 23:32 UTC, according to Nexqual real-time market data.
SPHRY last closed at USD 5.8; the session ranged USD 5.35–5.35 on volume of 1,000 shares. Market capitalization is $255.22M, with a 52-week range of USD 0.74–5.82 (OQX). Source: Nexqual, September 9, 2026 at 23:32 UTC.
Key Statistics (as of September 9, 2026 at 23:32 UTC)
| Price | USD 5.35 |
|---|---|
| Change | ▼ 7.76% (down) |
| Previous Close | USD 5.8 |
| Open | USD 5.35 |
| Day Range | USD 5.35 – 5.35 |
| 52-Week Range | USD 0.74 – 5.82 |
| Volume | 1,000 shares |
| Market Cap | $255.22M |
| Exchange | OQX |
Technical Analysis (SPHRY)
Nexqual's technical model rates SPHRY "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of September 9, 2026 at 23:32 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 56.59 (neutral) |
| vs SMA50 | Above (USD 4.97) |
| MACD | 0.11 (positive) |
Analyst Ratings (SPHRY)
Wall Street analysts rate SPHRY "None", per Nexqual as of September 9, 2026 at 23:32 UTC.
| Consensus Rating | None |
|---|
Earnings (SPHRY)
Source: Nexqual, September 9, 2026 at 23:32 UTC.
Financials & Fundamentals (SPHRY)
| Total Revenue | $12.67M |
|---|---|
| Revenue Growth (YoY) | -55.80% |
| Gross Margin | +6.11% |
| Operating Margin | -583.74% |
| Profit Margin | -58.93% |
| ROE | -45.55% |
| Debt / Equity | 5.13 |
| Current Ratio | 3.4 |
| Total Cash | $11.02M |
| Total Debt | $707,000 |
| Free Cash Flow | $-708,625 |
Source: Nexqual, September 9, 2026 at 23:32 UTC.
Financial Health Score (SPHRY)
Nexqual rates SPHRY's overall financial health "Weak" across five dimensions, as of September 9, 2026 at 23:32 UTC.
| Growth | Critical — Revenue -56% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $11M cash, no debt |
| Cash Flow | Weak — FCF negative: -$709K, burning cash |
| Efficiency | Critical — ROE -46%, ROA -21.0% |
Ownership (SPHRY)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 47.71M |
| Float | 35.00M |
Source: Nexqual, September 9, 2026 at 23:32 UTC.
Leadership (SPHRY)
SPHRY is led by Miranda Sowden, Director of People & Culture, per Nexqual as of September 9, 2026 at 23:32 UTC.
| Director of People & Culture | Miranda Sowden |
|---|
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SPHRF | STARPHARMA HOLDINGS LIMITED | USD 0.47 | ▲ 0% |
| CUVL | Clinuvel Pharmaceuticals Limite | USD 5.93 | ▼ 9.05% |
| SNPHY | Santen Pharmaceutical Co., Ltd. | USD 11.5 | ▼ 1.96% |
| SPL.AX | STARPHARMA FPO [SPL] | AUD 0.81 | ▲ 1.89% |
| ACCL | Acco Group Holdings Limited | USD 3.1 | ▲ 13.14% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 23:32 UTC. This page is informational and not investment advice.